Biotech Values

[DewDiligence]

I think Tofacitinib has an 85% chance of approval by the Aug 2012 PDUFA date. Basically concur with genisi’s assessment in #msg-75539892—i.e. the unmet medical need will trump the ambiguity wrt Tofacitinib’s results in the (non-primary endpoint) of radiographic progression relative to the control arm.

I expect the FDA to grant a third-line label; if the FDA grants a second-line label, it will be a pretty big win for PFE, IMHO.